TAVR may be a safe, effective treatment strategy for patients with moderate aortic stenosis and at least one other warning sign of heart disease. That was the key takeaway from a highly anticipated late-breaking study presented by Philippe Généreux, MD, at TCT 2026 in San Diego.
